Fight CRC Clinical Trial Finder
| NCT ID | Title | 阶段 | Date Added | 地点 | Prior IO Allowed | CRC-directed | Status | 药物 | 标签 |
|---|---|---|---|---|---|---|---|---|---|
| NCT ID NCT05768503 |
TitleComparing Chidamide+Sintilimab+Bev With Standard Second-line FOLFIRI+Bev in Advanced MSS/pMMR mCRC | 阶段
第三阶段
|
Date Added 2023-03-14 |
地点
中国
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
招聘
|
药物
Control Rx, Experimental drug |
标签
MSS/ MMRp
|
| NCT ID NCT05759728 |
Title针对转移性结直肠癌受试者的 CNA3103（LGR5 靶向自体 CAR-T 细胞）研究 | 阶段
第 1 阶段
|
Date Added 2023-03-08 |
地点
澳大利亚
|
Prior IO Allowed 是 |
CRC-directed 是 |
Status
招聘
|
药物 |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT05743036 |
TitleZN-c3 in Adult Participants With BRAF mutant Metastatic Colorectal Cancer | 阶段
第 1 阶段
|
Date Added 2023-02-24 |
地点
California, United States
Kansas, United States Texas, United States 澳大利亚 德国 Hungary 意大利 波兰 西班牙 |
Prior IO Allowed 是 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
cetuximab, encorafenib, ZN-c3 |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT05733611 |
TitleRP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC | 阶段
第二阶段
|
Date Added 2023-02-17 |
地点 |
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
活跃，非招募
|
药物 |
标签
MSS/ MMRp
|
| NCT ID NCT05726864 |
TitleA Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors | 阶段
Phase 1, Phase 2
|
Date Added 2023-02-14 |
地点
Arizona, United States
California, United States Colorado, United States Florida, United States Georgia, United States Iowa, United States Louisiana, United States Massachusetts, United States Michigan, United States Minnesota, United States New York, United States Pennsylvania, United States Tennessee, United States Texas, United States Wisconsin, United States |
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
ELI-002 7P |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT05722327 |
TitlePhase I Trial of Adagrasib (MRTX849) in Combination With Cetuximab and Irinotecan in Patients With Colorectal Cancer | 阶段
第 1 阶段
|
Date Added 2023-02-10 |
地点
Texas, United States
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
cetuximab, Irinotecan, MRTX849 |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT05714553 |
TitleNUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours | 阶段
Phase 1, Phase 2
|
Date Added 2023-02-06 |
地点
英国
|
Prior IO Allowed 是 |
CRC-directed 是 |
Status
招聘
|
药物
Docetaxel, Fosifloxuridine Nafalbenamide, Leucovorin, Pembrolizumab |
标签
MSI-H/ MMRd
|
| NCT ID NCT05684211 |
Title阿美单抗与抗 PD-1 单克隆抗体和 FOLFIRI 联合用于 RAS 野生型晚期结直肠癌患者的研究 | 阶段
第二阶段
|
Date Added 2023-01-13 |
地点
中国
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
尚未招聘
|
药物
阿米妥单抗 |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT05677113 |
TitleA Study of QBECO Versus Placebo in the Treatment of Colorectal Cancer That Has Spread to the Liver | 阶段
第二阶段
|
Date Added 2023-01-10 |
地点
加拿大
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
招聘
|
药物
Placebo, QBECO |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT05676190 |
TitleClinical Study on the Efficacy of Autologous Cell Factor Induced Killer Cells in the Treatment of Colorectal Cancer | 阶段
不适用
|
Date Added 2023-01-09 |
地点
中国
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
招聘
|
药物 |
标签
MSI-H/ MMRd, MSS/ MMRp
|
